NCT04152161View on ClinicalTrials.gov

Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained Infection

PHASE2TerminatedINTERVENTIONAL
Enrollment

1,836

Participants

Timeline

Start Date

October 16, 2019

Primary Completion Date

May 14, 2024

Study Completion Date

May 14, 2024

Conditions
Tuberculosis
Interventions
BIOLOGICAL

BCG vaccine SSI

Participants will receive a single 0.1 milliliter (mL) volume of BCG vaccine SSI, administered intradermally in deltoid region of the upper arm.

BIOLOGICAL

Placebo

Participants will receive a single 0.1 mL volume of normal saline, administered intradermally in deltoid region of the upper arm.

Trial Locations (5)

2001

Investigational Site, Hillbrow

4001

Investigational Site, Berea

6850

Investigational Site, Worcester

7626

Investigational Site, Paarl

7750

Investigational Site, Klipfontein

Sponsors
All Listed Sponsors
lead

Gates Medical Research Institute

OTHER